| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JHEP.2010.03.013 |
| P698 | PubMed publication ID | 20570385 |
| P50 | author | Jaime Bosch | Q61107953 |
| Annalisa Berzigotti | Q88161349 | ||
| P2093 | author name string | Puneeta Tandon | |
| Juan G Abraldes | |||
| Juan Carlos Garcia-Pagan | |||
| P433 | issue | 2 | |
| P921 | main subject | meta-analysis | Q815382 |
| systematic review | Q1504425 | ||
| P304 | page(s) | 273-282 | |
| P577 | publication date | 2010-05-21 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis | |
| P478 | volume | 53 |
| Q43787030 | 6 years of the International Union of Societies of Immunology. Presidential report (Brighton 1974) |
| Q57108060 | Activation of RAAS in a rat model of liver cirrhosis: no effect of losartan on renal sodium excretion |
| Q59811968 | Advances in therapeutic options for portal hypertension |
| Q87850418 | Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials |
| Q90680432 | Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats |
| Q41247731 | Changes in Hepatic Venous Pressure Gradient Induced by Physical Exercise in Cirrhosis: Results of a Pilot Randomized Open Clinical Trial |
| Q34399357 | Clinical Pharmacology of Portal Hypertension |
| Q35651447 | Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis |
| Q89869274 | Decreased potency of fimasartan in liver cirrhosis was quantified using mixed-effects analysis |
| Q39537347 | Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis. |
| Q38168180 | Drug therapies in liver disease. |
| Q84785198 | Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial |
| Q38826464 | Emerging therapies for portal hypertension in cirrhosis |
| Q34446521 | Future therapy of portal hypertension in liver cirrhosis - a guess |
| Q38218607 | Future treatments of cirrhosis |
| Q36387949 | Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis |
| Q26864350 | Hepatosplanchnic circulation in cirrhosis and sepsis |
| Q87200165 | Liver cirrhosis |
| Q91940739 | Liver-Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug-Resistant Gene 2-Knockout Mice |
| Q37832507 | Management of varices in cirrhosis |
| Q37838441 | Medical management of ascites |
| Q38021413 | New therapeutic paradigm for patients with cirrhosis |
| Q38680437 | Novel treatment options for portal hypertension |
| Q39429850 | Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon |
| Q39607845 | Pathophysiology of portal hypertension and esophageal varices |
| Q39067320 | Prevention and treatment of variceal haemorrhage in 2017. |
| Q26852622 | Primary prevention of variceal bleeding: pharmacological therapy versus endoscopic banding |
| Q37810525 | Primary prevention of variceal hemorrhage. |
| Q43183668 | Quantitative modeling of the physiology of ascites in portal hypertension |
| Q38268965 | Recent advances in cirrhotic cardiomyopathy |
| Q35931751 | Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review |
| Q55363090 | Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension. |
| Q34222291 | Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. |
| Q47863448 | Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. |
| Q52570905 | The selective mineralcorticoid receptor (MR) antagonist eplerenon prevents decompensation of liver cirrhosis. |
| Q36769062 | Therapeutic potential of targeting the renin angiotensin system in portal hypertension. |
| Q95025125 | Treatment update on portal hypertension and complications |
| Q38006726 | Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. |
| Q47106953 | Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma |
Search more.